Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

82 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer.
Antonia SJ, Villegas A, Daniel D, Vicente D, Murakami S, Hui R, Yokoi T, Chiappori A, Lee KH, de Wit M, Cho BC, Bourhaba M, Quantin X, Tokito T, Mekhail T, Planchard D, Kim YC, Karapetis CS, Hiret S, Ostoros G, Kubota K, Gray JE, Paz-Ares L, de Castro Carpeño J, Wadsworth C, Melillo G, Jiang H, Huang Y, Dennis PA, Özgüroğlu M; PACIFIC Investigators. Antonia SJ, et al. Among authors: ostoros g. N Engl J Med. 2017 Nov 16;377(20):1919-1929. doi: 10.1056/NEJMoa1709937. Epub 2017 Sep 8. N Engl J Med. 2017. PMID: 28885881 Free article. Clinical Trial.
Targeting blood vessels for the treatment of non-small cell lung cancer.
Amir E, Hughes S, Blackhall F, Thatcher N, Ostoros G, Timar J, Tovari J, Kovacs G, Dome B. Amir E, et al. Among authors: ostoros g. Curr Cancer Drug Targets. 2008 Aug;8(5):392-403. doi: 10.2174/156800908785133187. Curr Cancer Drug Targets. 2008. PMID: 18690845 Review.
High VEGFR-3-positive circulating lymphatic/vascular endothelial progenitor cell level is associated with poor prognosis in human small cell lung cancer.
Bogos K, Renyi-Vamos F, Dobos J, Kenessey I, Tovari J, Timar J, Strausz J, Ostoros G, Klepetko W, Ankersmit HJ, Lang G, Hoda MA, Nierlich P, Dome B. Bogos K, et al. Among authors: ostoros g. Clin Cancer Res. 2009 Mar 1;15(5):1741-6. doi: 10.1158/1078-0432.CCR-08-1372. Epub 2009 Feb 24. Clin Cancer Res. 2009. PMID: 19240177
Lung cancer in never smokers.
Torok S, Hegedus B, Laszlo V, Hoda MA, Ghanim B, Berger W, Klepetko W, Dome B, Ostoros G. Torok S, et al. Among authors: ostoros g. Future Oncol. 2011 Oct;7(10):1195-211. doi: 10.2217/fon.11.100. Future Oncol. 2011. PMID: 21992731 Free article. Review.
SELECT-2: a phase II, double-blind, randomized, placebo-controlled study to assess the efficacy of selumetinib plus docetaxel as a second-line treatment of patients with advanced or metastatic non-small-cell lung cancer.
Soria JC, Fülöp A, Maciel C, Fischer JR, Girotto G, Lago S, Smit E, Ostoros G, Eberhardt WEE, Lishkovska P, Lovick S, Mariani G, McKeown A, Kilgour E, Smith P, Bowen K, Kohlmann A, Carlile DJ, Jänne PA. Soria JC, et al. Among authors: ostoros g. Ann Oncol. 2017 Dec 1;28(12):3028-3036. doi: 10.1093/annonc/mdx628. Ann Oncol. 2017. PMID: 29045535 Free PMC article. Clinical Trial.
82 results